FDA requests additional Arxxant trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Lilly "is weighing options for the further development" of its diabetic retinopathy treatment Arxxant (ruboxistaurin) following an FDA request for "an additional, three-year, Phase III clinical trial," the company says Sept. 29. "Lilly believes that such a trial would require up to five years to complete." The news follows a meeting with FDA to discuss options for responding to an "approvable" letter issued in August, at which time Lilly had suggested the possibility of an additional trial (1Pharmaceutical Approvals Monthly September 2006, p. 2)...
You may also be interested in...
Lilly Arxxant "approvable"
Lilly believes it may have to conduct an additional trial of Arxxant (ruboxistaurin) following receipt of an Aug. 17 "approvable" letter. The firm said it plans to meet with FDA to determine whether the agency's request for additional data could be supported by data from an ongoing trial. In July, Lilly announced a co-promotion deal for Arxxant with Alcon (1Pharmaceutical Approvals Monthly August 2006, p. 2)...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.